Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

WesternU professor among top neuroscientists in the world

WesternU Graduate College of Biomedical Sciences Professor Michel Baudry, PhD, was recently inducted as a Fellow of the American Association for the Advancement of Science (AAAS). This prestigious honor recognizes 40 years of achievement in neuroscience and comes at a momentous time in the development of his life's work.


News provided by

Western University of Health Sciences

Feb 22, 2021, 12:00 ET

Share this article

Share toX

Share this article

Share toX

WesternU Professor Michel Baudry, PhD, was inducted as a Fellow of the American Association for the Advancement of Science. (Jeff Malet, WesternU)
WesternU Professor Michel Baudry, PhD, was inducted as a Fellow of the American Association for the Advancement of Science. (Jeff Malet, WesternU)

POMONA, Calif., Feb. 22, 2021 /PRNewswire-PRWeb/ -- In a journey of discovery that has spanned from France to Southern California, Western University of Health Sciences Graduate College of Biomedical Sciences Professor Michel Baudry, PhD, has reached a pivotal moment in his career.

Baudry was inducted as a Fellow of the American Association for the Advancement of Science (AAAS) on Feb. 8, 2021. This prestigious honor recognizes 40 years of achievement in neuroscience and comes at a momentous time in the development of his life's work.

“I love my research. I love the process. I love the challenges and the ‘Eureka moments,’ when you see something no one has ever seen before."-WesternU Professor Michel Baudry

Post this

His research into the mechanisms of learning and memory - specifically in the roles of the calcium-dependent proteases calpain-1 and calpain-2 in neuroprotection and neurodegeneration - has culminated in the development of a molecule that could have wide-ranging impact on treating concussions and other traumatic brain injuries.

"We have now reached a point with our research where we are ready to move into translation, and we hope to start clinical trials in 2022," Baudry said. "So all these years of hard work not only are being recognized by my peers, but have also led to something that could have broad societal implications and health care implications. As we get older, what we want people to see is not only the body of work we have done, but also the translation of this body of work."

Baudry was elected as an AAAS Fellow in the Section on Neuroscience for "distinguished contributions to the field of molecular and translational neuroscience, in particular, to the understanding of the roles of calpain-1 and calpain-2 in synaptic plasticity and neurodegeneration."

Becoming an AAAS Fellow is also a message for the younger generation, Baudry said. "The process works. You do research, you get recognized for your work," he said.

In his 42 years as a researcher, he has worked with 18 postdocs, 35 graduate students, many undergraduates and obtained more than $12 million in grants and contracts. He has a number of WesternU students working in his lab, as well as undergraduates from neighboring institutions.

"This is also part of my mission to train and inform the next generation of scientists," he said. "I love graduate students. I do think this is an important part of what we do, to not only to do science, but also to educate and train the next generation of scientists. Ultimately what you want is when these students graduate, they have learned the research process. They learned that research is exciting and that research works. The point is you make discoveries no one has made before."

Baudry earned his PhD in France in 1977 and moved to the U.S. in 1978 for postdoctoral work at the University of California, Irvine with Dr. Gary Lynch. He wanted to understand the molecular mechanism of Long-Term Potentiation (LTP), a cellular model of learning and memory. He moved on to USC from 1989-2011, with many ups and downs as he explored avenues, ran into dead ends, and eventually found the right path – calpain.

Caleb Finch, PhD, Professor and ARCO/William F. Kieschnick Chair in the Neurobiology of Aging at the USC Leonard Davis School of Gerontology, has been a colleague and collaborator of Baudry's for 45 years, first meeting when Baudry was at UC Irvine and then working together when both were at USC.

"He's a person of wonderful intellectual energy, very positive, and a great person to sit down and design experiments with, look at difficult data, or have a glass of wine with at the end of the day," Finch said. "He represents the joie de vivre of the French culture both intellectually and socially."

Baudry has had tremendous successes through the years, but science is also full of gut-wrenching disappointments, Finch said.

"If every experiment worked, you're not doing interesting experiments," he said. "(Baudry) has done a lot of difficult, probing, pioneering experiments that had multiple interpretations that required more experiments to dig into the actual mechanisms.

"Michel is clearly among the top 100 neuroscientists who really moved the field forward," Finch added. "And there are probably 50,000 neuroscientists worldwide right now."

Baudry joined WesternU in 2012, and his research into the roles of calpain-1 and calpain-2 continued to produce results using a mouse model.

"We found calpain-1 is neuroprotective. You need calpain-1 to protect and calpain-2 is critical for neurodegeneration," Baudry said. "If we have a selected way to inhibit calpain-2, this inhibitor could have two effects. It could facilitate learning and it could be neuroprotective when you have an insult to the brain."

Starting a Phase I clinical trial in 2022 might allow his discovery to be brought to market as a neuroprotector.

"We have shown we can protect mice from the pathological consequences of concussion and traumatic brain injury. Now we need to show it works in humans. That is the only thing left for me to do. Once we do that, I can just take a big break," Baudry said. "How many scientists have the ability to get a shot on goal? I have a shot on goal. Now we can prove or disprove that what we found in animals is working on humans. I cannot wait to be in the clinic.

"I love my research. I love the process. I love the challenges and the 'Eureka moments,' when you see something no one has ever seen before," Baudry said. "That's the reward. The reward is indeed the discovery. That's exciting."

Media Contact

Rodney Tanaka, Western University of Health Sciences, 909-469-5402, [email protected]

SOURCE Western University of Health Sciences

Related Links

http://www.westernu.edu

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.